{
    "root": "2fffae44-e508-9645-e063-6394a90a7ce5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin calcium",
    "value": "20250310",
    "ingredients": [
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        }
    ],
    "indications": "atorvastatin calcium tablets indicated : reduce risk : myocardial infarction ( myocardial infarction ) , stroke , revascularization procedures , angina adults multiple risk factors coronary heart disease ( chd ) without clinically evident chd myocardial infarction stroke adults type 2 diabetes mellitus multiple risk factors chd without clinically evident chd non-fatal myocardial infarction , fatal non-fatal stroke , revascularization procedures , hospitalization congestive heart failure , angina adults clinically evident chd adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 10 years older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia hypertriglyceridemia",
    "contraindications": "take orally daily without food ( 2.1 ) . assess ldl-c clinically appropriate , early 4 weeks initiating atorvastatin calcium tablets , adjust necessary ( 2.1 ) . adults ( 2.2 ) : recommended starting 10 20 mg daily ; range 10 mg 80 mg daily . patients requiring ldl-c reduction > 45 % may start 40 mg daily . pediatric patients aged 10 years age older hefh : recommended starting 10 mg daily ; range 10 20 mg daily ( 2.3 ) . pediatric patients aged 10 years age older hofh : recommended starting 10 20 mg daily ; range 10 80 mg daily ( 2.4 ) . full prescribing information atorvastatin calcium tablets modifications due ( 2.5 ) .",
    "warningsAndPrecautions": "atorvastatin calcium tablets , usp 10 mg ( 10 mg atorvastatin ) : white , oval shaped , film-coated tablet `` ls `` debossed one side tablet `` 247 `` debossed side tablet . ndc 70756-247-30 bottles 30 child-resistant closure ndc 70756-247-90 bottles 90 child-resistant closure ndc 70756-247-51 bottles 500 ndc 70756-247-12 bottles 1000 atorvastatin calcium tablets , usp 20 mg ( 20 mg atorvastatin ) : white , oval shaped , film-coated tablet `` ls `` debossed one side tablet `` 248 `` debossed side tablet . ndc 70756-248-30 bottles 30 child-resistant closure ndc 70756-248-90 bottles 90 child-resistant closure ndc 70756-248-51 bottles 500 ndc 70756-248-12 bottles 1000 atorvastatin calcium tablets , usp 40 mg ( 40 mg atorvastatin ) : white , oval shaped , film-coated tablet `` ls `` debossed one side tablet `` 249 `` debossed side tablet . ndc 70756-249-30 bottles 30 child-resistant closure ndc 70756-249-90 bottles 90 child-resistant closure ndc 70756-249-51 bottles 500 ndc 70756-249-12 bottles 1000 atorvastatin calcium tablets , usp 80 mg ( 80 mg atorvastatin ) : white , oval shaped , film-coated tablet `` ls `` debossed one side tablet `` 250 `` debossed side tablet . ndc 70756-250-30 bottles 30 child-resistant closure ndc 70756-250-90 bottles 90 child-resistant closure ndc 70756-250-51 bottles 500 storage store 20°c 25°c ( 68°f 77°f ) . [ usp controlled room temperature ] .",
    "adverseReactions": "acute liver failure decompensated cirrhosis [ ( 5.3 ) ] hypersensitivity atorvastatin excipients atorvastatin calcium tablets . hypersensitivity , including anaphylaxis , angioneurotic edema , erythema multiforme , stevens-johnson syndrome , toxic epidermal necrolysis , reported [ ( 6.2 ) ] .",
    "indications_original": "Atorvastatin calcium tablets are indicated:\n                  \n                     \n                     \n                        \n                           \n                              \n                                 To reduce the risk of:\n                              o   Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD \n       o   MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD \n       o   Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD \n     \n                              \n                                 As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n                              o   Adults with primary hyperlipidemia. \n       o   Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). \n     \n                              \n                                 As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                                 As an adjunct to diet for the treatment of adults with:\n                              o   Primary dysbetalipoproteinemia \n       o   Hypertriglyceridemia",
    "contraindications_original": "Take orally once daily with or without food (2.1). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary (2.1). Adults (2.2): o    Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. o    Patients requiring LDL-C reduction >45% may start at 40 mg once daily. Pediatric Patients Aged 10 Years of Age and Older with HeFH : Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily (2.3). Pediatric Patients Aged 10 Years of Age and Older with HoFH : Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily (2.4). See full prescribing information for atorvastatin calcium tablets dosage modifications due to drug interactions (2.5).",
    "warningsAndPrecautions_original": "Atorvastatin calcium tablets, USP 10 mg(10 mg of atorvastatin): White, oval shaped, film-coated tablet with \"LS\" debossed on one side of the tablet and \"247\" debossed on the other side of the tablet.\n\n \n                  NDC 70756-247-30           bottles of 30 with child-resistant closure\n                  NDC 70756-247-90           bottles of 90 with child-resistant closure\n                  NDC 70756-247-51           bottles of 500\n                  NDC 70756-247-12           bottles of 1000\n                  \n                     Atorvastatin calcium tablets, USP 20 mg(20 mg of atorvastatin): White, oval shaped, film-coated tablet with \"LS\" debossed on one side of the tablet and \"248\" debossed on the other side of the tablet.\n\n \n                  NDC 70756-248-30           bottles of 30 with child-resistant closure\n                  NDC 70756-248-90           bottles of 90 with child-resistant closure\n                  NDC 70756-248-51           bottles of 500\n                  NDC 70756-248-12           bottles of 1000\n                  \n                     Atorvastatin calcium tablets, USP 40 mg(40 mg of atorvastatin):\n \n   White, oval shaped, film-coated tablet with \"LS\" debossed on one side of the tablet and \"249\" debossed on the other side of the tablet.\n\n \n                   NDC 70756-249-30           bottles of 30 with child-resistant closure\n                  NDC 70756-249-90           bottles of 90 with child-resistant closure\n                  NDC 70756-249-51           bottles of 500\n                  NDC 70756-249-12           bottles of 1000\n                  \n                     Atorvastatin calcium tablets, USP 80 mg(80 mg of atorvastatin): White, oval shaped, film-coated tablet with \"LS\" debossed on one side of the tablet and \"250\" debossed on the other side of the tablet.\n\n \n                  NDC 70756-250-30           bottles of 30 with child-resistant closure\n                  NDC 70756-250-90           bottles of 90 with child-resistant closure\n                  NDC 70756-250-51           bottles of 500\n                  Storage\n                  Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Acute liver failure or decompensated cirrhosis\n  \n   [see Warnings and Precautions (5.3)]\n                     \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium tablets. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n  \n   [see Adverse Reactions (6.2)]."
}